Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence

References

• Bauman A, Phongsavan P. Epidemiology of substance use in adolescence: prevalence, trends and policy implications. Drug Alcohol Depend.55(3), 187–207 (1999).
   PubMed Web of Science ®Google Scholar
• United Nations Office of Drug Control. 2007 World Drug Report. UNODC 282 (2007).
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. In: NSDUH Series H-30. Rockville, MD, USA (2006).
   Google Scholar
• Anthony JC Warner L, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants : basic findings from the national comorbidity survey. Exp. Clin. Psychopharmacol.2, 244–268 (1994).
   Web of Science ®Google Scholar
• Bhana A, Parry CD, Myers B, Pluddemann A, Morojele NK, Flisher AJ. The South African Community Epidemiology Network on Drug Use (SACENDU) project, phases 1–8 – cannabis and Mandrax. S. Afr. Med. J.92(7), 542–547 (2002).
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Simpson EE. Adult marijuana users seeking treatment. J. Consult. Clin. Psychol.61(6), 1100–1104 (1993).
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Service Administration OoAS. In: Treatment Episode Data Set (TEDS). Rockville, MD, USA (2002)
   Google Scholar
• Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry161(11), 1967–1977 (2004).
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry184, 110–117 (2004).
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry57(10), 1117–1127 (2005).
   PubMed Web of Science ®Google Scholar
• Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull.31(3), 608–612 (2005).
   PubMed Web of Science ®Google Scholar
• Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet370(9584), 319–328 (2007).
   PubMed Web of Science ®Google Scholar
• McRae AL, Budney AJ, Brady KT. Treatment of marijuana dependence: a review of the literature. J. Subst. Abuse Treat.24(4), 369–376 (2003).
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl.)155(2), 171–179 (2001).
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl.)165(2), 157–165 (2003).
   PubMed Web of Science ®Google Scholar
• Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl.)166(1), 77–85 (2003).
   PubMed Web of Science ®Google Scholar
• Donovan SJ, Stewart JW, Nunes EV et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am. J. Psychiatry157(5), 818–820 (2000).
   PubMed Web of Science ®Google Scholar
• Coplan JD, Gorman JM. Treatment of anxiety disorder in patients with mood disorders. J. Clin. Psychiatry51(Suppl.), 9–13; discussion 14–17 (1990).
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Vosburg SK et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology29(1), 158–170 (2004).
   PubMed Web of Science ®Google Scholar
• Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral d-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend.86(1), 22–29 (2007).
   PubMed Web of Science ®Google Scholar
• Frewen A, Baillie A, Rea F. The role of mirtazapine in cannabis withdrawal. In: College of Problems on Drug Dependence. Quebec, Canada (2007).
   Google Scholar
• Huestis MA, Gorelick DA, Heishman SJ et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry58(4), 322–328 (2001).
   PubMed Web of Science ®Google Scholar
• Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend.67(3), 301–309 (2002).
   PubMed Web of Science ®Google Scholar
• Levin FR, McDowell D, Evans SM et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am. J. Addict.13(1), 21–32 (2004).
   PubMed Web of Science ®Google Scholar
• McRae AL, Brady KT, Carter RE. Buspirone for treatment of marijuana dependence: a pilot study. Am. J. Addict.15(5), 404 (2006).
   PubMed Web of Science ®Google Scholar
• Tirado CF, Goldman M, Lynch K, Kampman KM, O’Brien CP. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. In: College of Problems on Drug Dependence. Quebec, Canada (2007).
   Google Scholar
• Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J. Consult. Clin. Psychol.62(1), 92–99 (1994).
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J. Consult. Clin. Psychol.68(5), 898–908 (2000).
   PubMed Web of Science ®Google Scholar
• Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive–behavioral interventions for cannabis use disorder. J. Subst. Abuse Treat.21(2), 55–64; discussion 65–66 (2001).
   PubMed Web of Science ®Google Scholar
• Brief treatments for cannabis dependence: findings from a randomized multisite trial. J. Consult. Clin. Psychol.72(3), 455–466 (2004).
   PubMed Web of Science ®Google Scholar
• Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J. Consult. Clin. Psychol.68(6), 1051–1061 (2000).
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive–behavioral therapy for cannabis dependence. J. Consult. Clin. Psychol.74(2), 307–316 (2006).
   PubMed Web of Science ®Google Scholar
• Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict. Behav.32(6), 1220–1236 (2007).
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Fearer SA, Williams C, Burke RS. The Marijuana Check-up: promoting change in ambivalent marijuana users. Addiction102(6), 947–957 (2007).
   PubMed Web of Science ®Google Scholar
• Sinha R, Easton C, Kemp K et al. Substance abuse treatment characteristics of probation-referred young adults in a community-based outpatient program. Am. J. Drug Alcohol Abuse29(3), 585–597 (2003).
   PubMed Web of Science ®Google Scholar
• Carroll KM, Easton CJ, Nich C et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J. Consult. Clin. Psychol.74(5), 955–966 (2006).
   PubMed Web of Science ®Google Scholar
• Dennis M, Godley SH, Diamond G et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J. Subst. Abuse Treat.27(3), 197–213 (2004).
   PubMed Web of Science ®Google Scholar
• Martin G, Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J. Subst. Abuse Treat. PMID: 17869051 (2007) (Epub ahead of print).
   Google Scholar
• Martin G, Copeland J, Swift W. The Adolescent Cannabis Check-Up: feasibility of a brief intervention for young cannabis users. J. Subst. Abuse Treat.29(3), 207–213 (2005).
   PubMed Web of Science ®Google Scholar
• Walker DD, Roffman RA, Stephens RS, Wakana K, Berghuis J, Kim W. Motivational enhancement therapy for adolescent marijuana users: a preliminary randomized controlled trial. J. Consult. Clin. Psychol.74(3), 628–632 (2006).
   PubMed Web of Science ®Google Scholar
• Roffman R, Stephens RS. Cannabis Dependence: Its Nature, Consequences, and Treatment. Edwards PG (Ed.), Cambridge University Press, Cambridge, UK (2006).
   Google Scholar
• Copeland J, Maxwell JC. Cannabis treatment outcomes among legally coerced and non-coerced adults. BMC Public Health7, 111 (2007).
   PubMed Web of Science ®Google Scholar
• Burleson JA, Kaminer Y, Dennis ML. Absence of iatrogenic or contagion effects in adolescent group therapy: findings from the Cannabis Youth Treatment (CYT) study. Am. J. Addict.15(Suppl. 1), 4–15 (2006).
   PubMed Web of Science ®Google Scholar
• Olmstead TA, Sindelar JL, Easton CJ et al. The cost–effectiveness of four treatments for marijuana dependence. Addiction102(9), 1443–1453 (2007).
   PubMed Web of Science ®Google Scholar
• Kleber HD, Weiss RD, Anton RF Jr et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am. J. Psychiatry164(4 Suppl.), 5–123 (2007).
   PubMed Web of Science ®Google Scholar
• Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr. Bull.32(4), 637–643 (2006).
   PubMed Web of Science ®Google Scholar
• Green AI, Tohen MF, Hamer RM et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res.66(2–3), 125–135 (2004).
   PubMed Web of Science ®Google Scholar
• Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmstetter B. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophr. Bull.32(3), 464–473 (2006).
   PubMed Web of Science ®Google Scholar
• Drake RE, Xie H, McHugo GJ, Shumway M. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders. Biol. Psychiatry56(10), 749–756 (2004).
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr. Scand.115(4), 304–309 (2007).
   PubMed Web of Science ®Google Scholar
• Xie H, McHugo GJ, Fox MB, Drake RE. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders. Psychiatr. Serv.56(10), 1282–1287 (2005).
   PubMed Web of Science ®Google Scholar